Recombinant Human Lysyl oxidase homolog 1 (LOXL1), partial

^{In
Stock}

文獻(xiàn)引用 (1)

中文名稱：

人LOXL1重組蛋白
品名簡(jiǎn)稱：

Recombinant Human LOXL1 protein, partial
貨號(hào)：

CSB-EP013040HU
說(shuō)明書(shū)：

MSDS Datasheet
規(guī)格：

￥1344
圖片：
(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP013040HU could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) LOXL1.

Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP013040HU could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) LOXL1.
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
引用文獻(xiàn)
相關(guān)產(chǎn)品
問(wèn)答及客戶評(píng)論
靶點(diǎn)詳情

產(chǎn)品詳情

純度：

Greater than 90% as determined by SDS-PAGE.
基因名：

LOXL1
Uniprot No.：

Q08397
別名：

LOXL1; LOXLLysyl oxidase homolog 1; EC 1.4.3.-; Lysyl oxidase-like protein 1; LOL
種屬：

Homo sapiens (Human)
蛋白長(zhǎng)度：

Partial
來(lái)源：

E.coli
分子量：

55.8kDa
表達(dá)區(qū)域：

106-574aa
氨基酸序列

VGSDTVRGQARHPFGFGQVPDNWREVAVGDSTGMARARTSVSQQRHGGSASSVSASAFASTYRQQPSYPQQFPYPQAPFVSQYENYDPASRTYDQGFVYYRPAGGGVGAGAAAVASAGVIYPYQPRARYEEYGGGEELPEYPPQGFYPAPERPYVPPPPPPPDGLDRRYSHSLYSEGTPGFEQAYPDPGPEAAQAHGGDPRLGWYPPYANPPPEAYGPPRALEPPYLPVRSSDTPPPGGERNGAQQGRLSVGSVYRPNQNGRGLPDLVPDPNYVQASTYVQRAHLYSLRCAAEEKCLASTAYAPEATDYDVRVLLRFPQRVKNQGTADFLPNRPRHTWEWHSCHQHYHSMDEFSHYDLLDAATGKKVAEGHKASFCLEDSTCDFGNLKRYACTSHTQGLSPGCYDTYNADIDCQWIDITDVQPGNYILKVHVNPKYIVLESDFTNNVVRCNIHYTGRYVSATNCKIVQS
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.
蛋白標(biāo)簽：

N-terminal 6xHis-tagged
產(chǎn)品提供形式：

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
緩沖液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
儲(chǔ)存條件：

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
保質(zhì)期：

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
貨期：

3-7 business days
注意事項(xiàng)：

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
產(chǎn)品描述：

Like all recombinant proteins, this Recombinant Human LOXL1 protein was encoded by recombinant DNA. The recombinant DNA was introduced to a plasmid in which the gene of LOXL1 was cloned downstream of a promoter region. When the plasmid was introduced to the cells of E.coli, the E.coli’s own protein synthesis pathways would then result in the expression of the LOXL1 protein. And the next step was protein purification. The purity of this recombinant protein is 90%+ determined by SDS-PAGE.
LOXL1 belongs to LOX family proteins. Members of the LOX family are secreted by tumors and are the subject of extensive efforts aimed at understanding their roles in cancer. For instance, LOXL1 can protect glioma cells from anoikis and IR stresses, rendering cells resistant to apoptosis. In detail, LOXL1 is upregulated by the VEGFR-Src-CEBPA axis in suspended glioma cells, and LOXL1 and BAG2 proteins can interact in glioma cells, preventing BAG2-K186 ubiquitylation depending on LOXL1 enzymatic activity and stabilizing BAG2 to ultimately promote cell survival. Besides, the aggregation of the LOXL1 protein coupled with age-related decline in cellular proteostasis capabilities may result in a build-up of LOXL1 containing protein aggregates.
Datasheet & COA：

Please contact us to get it.

引用文獻(xiàn)

Lysyl Oxidase-Like 1 (LOXL1) Up-Regulation in Chondrocytes Promotes M1 Macrophage Activation in Osteoarthritis via NF-κB and STAT3 Signaling Y Jiang, S Wang, W Zhu, X Liu, Y Yang,ImmunoTargets and Therapy,2025

產(chǎn)品評(píng)價(jià)

問(wèn)答及客戶評(píng)論

■ 常見(jiàn)問(wèn)題解答

Regarding your protein CSB-EP013040HU, could you please advise on the lead time, the sequencing, the pricing, and the expected tag information?
Also, we need the buffer to be “10mM MES, pH 6.0 or 50mM Sodium borate buffer, pH 8.2 without any EDTA and DTT.”
Would this be possible?

Thanks for your inquiry.
Recombinant Human Lysyl oxidase homolog 1(LOXL1),partial
CSB-EP013040HU >> E.coli
Expression Region: 106-574aa; Partial.
Tag information:N-terminal 6xHis-tagged.
Sequence:

VGSDTVRGQARHPFGFGQVPDNWREVAVGDSTGMARARTSVSQQRHGGSASSVSASAFASTYRQQPSYPQQFPYPQAPFVSQYENYDPASRTYDQGFVYYRPAGGGVGAGAAAVASAGVIYPYQPRARYEEYGGGEELPEYPPQGFYPAPERPYVPPPPPPPDGLDRRYSHSLYSEGTPGFEQAYPDPGPEAAQAHGGDPRLGWYPPYANPPPEAYGPPRALEPPYLPVRSSDTPPPGGERNGAQQGRLSVGSVYRPNQNGRGLPDLVPDPNYVQASTYVQRAHLYSLRCAAEEKCLASTAYAPEATDYDVRVLLRFPQRVKNQGTADFLPNRPRHTWEWHSCHQHYHSMDEFSHYDLLDAATGKKVAEGHKASFCLEDSTCDFGNLKRYACTSHTQGLSPGCYDTYNADIDCQWIDITDVQPGNYILKVHVNPKYIVLESDFTNNVVRCNIHYTGRYVSATNCKIVQS

As you requested that the buffer be “10mM MES, pH 6.0 or 50mM Sodium borate buffer, pH 8.2 without any EDTA and DTT.”
Sorry, as we haven't tried this buffer before, we don't have raw material for these two kinds of buffer, is it possible for you to accept any other buffer that without any EDTA and DTT ?The final buffer will be determined during the manufacturing process.
We produced CSB-EP013040HU recently, the buffer is 100 mM Tris-HCl, 0.4 M Arg, pH 8.0, 20% glycerol,we can send the COA for your reference.

Thank you for the information you provided.
We really want the active form of this protein.I know that the lab does not test or QC for any kind of activity, but I'm still interested. Plese check the following note:
LOXL1 is an amine oxidase and its activity depends on a coordinated copper ion, therefore, having Tris (contains primary amines), EDTA and DTT might inhibit or kill its activity. Presumably, any buffer system other than Tris w/o EDTA and DTT should work however previous literature suggests that these enzymes have the best activity in Sodium Borate buffer, pH8.2.
Do you guys have any suggestions about another buffer?

Thanks for your inquiry.
Yes, we can't guarantee the activity. But we can try to prepare the protein according to your requirement.
We will purchase sodium borate to have a try, and provide the protein in the buffer of Sodium Borate buffer, pH8.2,
If the protein is not stable in this buffer, we will communicate with you in advance, if you finally accept the other buffer such as PBS, HEPES, CB buffer after the Sodium Borate buffer trial is failed,there isn't any extra charges for Sodium Borate buffer trial.
But if you don't accept any other buffer after the Sodium Borate buffer trail fails, there will be some extra charges.
The extra charges depends on which expression system you choose and which size you need.

收起更多

靶點(diǎn)詳情

功能：

Active on elastin and collagen substrates.
基因功能參考文獻(xiàn)：
1. the rs11638944:C>G transversion exerts a cis-acting effect on the expression levels of LOXL1, mediated by differential binding of the transcription factor retinoid X receptor alpha and by modulating alternative splicing of LOXL1, eventually leading to reduced levels of LOXL1 mRNA in cells and tissues of risk allele carriers for pseudoexfoliation syndrome PMID: 28534485
2. LOXL1/LOXL2 gene expression and protein levels were increased in Idiopathic pulmonary fibrosis (IPF) versus non-IPF. PMID: 29125826
3. These findings provide evidence for a functional role of alternative splicing coupled to NMD in the posttranscriptional regulation of LOXL1 gene expression and suggest this mechanism to represent a dynamic mode of adapting LOXL1 expression to PEX-associated environmental and nutritional cues. PMID: 29164236
4. remenopausal and postmenopausal women with Pelvic Organ Prolapse (POP) exhibit differential expression of LOXL1 suggesting different pathways in the pathogenesis of POP. The role of biopsy location on LOXL1 expression requires further investigation. PMID: 26829347
5. In this study, we found no significant association between allele and genotype frequencies of APOE; the intronic SNP rs2165241 and the non-synonymous SNP rs3825942 in exon 1 of LOXL1 are significantly associated with pseudoexfoliation syndrome and exfoliation glaucoma in the Turkish population. PMID: 27028259
6. A rare protective allele at LOXL1,Tyr407Phe, was identified. It is found exclusively in the Japanese population. It confers 25-fold resistance to XFS. It segregated with the common rs3825942[A] (p.Asp153) in all but 2 patients examined. In spheroids, this haplotype conferred a significant increase in the strength of cellular adhesion in comparison to 3 haplotypes with the wild-type allele. PMID: 28553957
7. Findings of this current study indicate a different LOXL1 gene expression pattern compared with a recent study that was also performed in the Turkish population. PMID: 27753755
8. LOXL1 transcriptional activity was dramatically reduced when a recombinant DNMT3A was concomitantly overexpressed. PMID: 27396912
9. The present study, for the first time, shows that the pseudoexfoliation syndrome-associated variant residues in LOXL1 influence processing of the protein, most likely by BMP-1. PMID: 26997634
10. In this study group of Turkish population, no LOXL1 mutations were found. No associations between the defined SNPs (A320A, R141L and F184F) and the severity of the disease were detected. PMID: 26758070
11. To identify additional candidate functional variants, we sequenced the entire LOXL1 genomic locus ( approximately 40 kb) in 50 indigenous, black South African XFS cases and 50 matched controls. PMID: 26307087
12. This is the first study associating two SNPs of LOXL1 (rs3825942 and rs2165241) and XFS/XFG in a Spanish population, confirming findings in patients from Europe. PMID: 24892565
13. Our meta-analysis indicates that rs1048661 had weak association with XFG/XFS; rs3825942 had strongly association with XFG/XFS; and rs2165241 had significant risk with XFG/XFS in some ethnicity. PMID: 25304275
14. CTR1, ATP7A, and lysyl oxidase were upregulated in the lung tissues and pulmonary arteries of mice with hypoxia-induced pulmonary hypertension and pulmonary arterial smooth muscle cells. PMID: 24614111
15. Different SNPs in LOXL1 affect risk of pseudoexfoliative glaucoma in different ethnic groups [meta-analysis] PMID: 26404116
16. When the LOXL1 variants were used as disease markers for clinically undetectable exfoliation syndrome (EX), there was no association between central retinal vein occlusion and EX. PMID: 25130441
17. results indicate that hypermethylation of CpG islands in the promoter region of the LOXL1 gene leads directly to downregulation of LOXL1 mRNA and protein, which functions as an essential mechanism in the pathogenesis of Pseudoexfoliation Syndrome PMID: 26348632
18. Data indicate that single-nucleotide polymorphisms (SNPs) distributing in not only lysyl oxidase-like 1 gene (LOXL1) but also TBC1 domain family member 21 protein (TBC1D21) and promyelocytic leukemia protein (PML). PMID: 24938310
19. Single nucleotide polymorphisms of the LOXL1 gene are associated with pseudoexfoliation glaucoma in the Spanish population. PMID: 26319397
20. The polymorphisms of the LOXL1 gene were associated with the susceptibility to primary open-angle glaucoma. PMID: 25750511
21. Our results demonstrate that only a small proportion of individuals with the high-risk GG/GG diplotype may actually be found to clinically manifest exfoliation syndrome. PMID: 25041436
22. Data suggest that expression of LOXL1 and FBLN5 (fibulin 5) (but not expression of elastin) is down-regulated in uterosacral ligaments of postmenopausal women with pelvic organ prolapse. PMID: 22487196
23. This polymorphism seems to be associated with high risk for primary open-angle glaucoma in a Mediterranean population. PMID: 24893574
24. p66beta might be important for the regulation of LOX in the nucleus. PMID: 25118846
25. There were no significant difference in allele frequency distribution of LOXL1 rs1048661rs3825942 and rs2165241 between primary open-angle glaucoma (POAG) and normal controls (P=0.322, P=0.660, P=0.965). PMID: 25636109
26. Pathogenetic stimuli induced a significant increase in the expression of LOXL1 and elastic proteins and resulted in their assembly into exfoliation syndrome-like fibrils in vitro. PMID: 25275906
27. Collectively, these results suggest that dysregulation of LOXL1 expression is a contributing factor to exfoliation disease development. PMID: 25275910
28. Human LOX gene encodes 2 variants, LOX and LOX-v2, both of which function as amine oxidases with distinct tissue specificities. PMID: 25017124
29. Studies suggest that LOXL1 rs1048661 TT, rs3825942 AA, and rs2165241 CC were associated with a reduced risk of developing pseudoexfoliation syndrome and pseudoexfoliation glaucoma (PEXS/PEXG). PMID: 24603551
30. Haplotypes of LOXL1 are associated with PG-PDS independently from rs1048661, leading to a differential expression of the transcript. PMID: 24739284
31. Sequencing of 7 exons and regulatory regions of LOXL1 identified 11 additional sequence variants; only rs41435250 showed an association (P = 3.80 x 10-5 [0.49]) with pseudoexfoliation syndrome and glaucoma PMID: 24809751
32. LOXL1 gene contributes to onset of PEXG through PEX. Gene variants of LOXL1 do not help to identify those with PEX at increased risk for glaucoma development. PMID: 24917141
33. allele T of LOXL1 rs41435250 is a novel risk genetic factor for pseudoexfoliation syndrome/pseudoexfoliation glaucoma development. PMID: 24068861
34. High Lysyl Oxidase expression is associated with non-small cell lung cancer. PMID: 23886154
35. LOXL1 is more abundant in the deposits in the iris region and, alternatively APOE is concentrated in the PEX material accumulated in the pupillary area of the anterior lens capsule. PMID: 23411028
36. The homozygote TT polymorphism in the rs1048661 and rs2165241 region of LOX-L1 gene may be responsible for stress urinary incontinance physiopathology. PMID: 22765198
37. Association of LOXL1 with exfoliation syndrome and exfoliation glaucoma was investigated and apolipoprotein E and MTHFR polymorphisms as genetic risk factors for both conditions, were evaluated. PMID: 23687437
38. Certain genetic variants in LOXL1 confer risk for pseudoexfoliation syndrome in Greek populations. PMID: 23869164
39. Three SNPs of LOXL1 (rs1048661, rs3825942, and 2,165,241) are highly associated with pseudoexfoliation syndrome in a Korean population. PMID: 23441117
40. None of the patients with exfoliation syndrome/glaucoma has the adenine (A) allele single nucleotide polymorphism (SNP) of rs3825942, whereas 16% of the control subjects have the LOXL1 variant. PMID: 23378724
41. Knockdown of E2F1 stabilized HIF-1alpha and promoted LOX expression, while knockdown of both E2F1 and HIF-1alpha prevented the up-regulation of LOX PMID: 23196386
42. There was no significant difference in the frequency of the DNA copy number variants in the LOXL1 region between the exfoliation glaucoma cases and the controls. PMID: 23288989
43. The -22G/C polymorphism may affect the expression of LOX, and that -22G/C and 473G/A polymorphisms may be new risk factors for osteosarcoma. PMID: 22911823
44. study suggests that LOX G473A polymorphism is a new risk factor for ovarian cancer and that LOX protein might be a possible therapeutic target in ovarian cancer PMID: 22906264
45. A significant association was found for the G allele of rs1048661 and rs3825942 in pseudoexfoliative glaucoma patients of Pakistani origin. PMID: 22605916
46. The findings provide evidence for a pseudoexfoliation-specific elastinopathy of the lamina cribrosa resulting from a primary disturbance in LOXL1 regulation and elastic fiber homeostasis. PMID: 22633114
47. The Saudi Arabian primary open angle glaucoma (POAG) population, similar to all other populations studied to date, demonstrates no association with SNPs associated with pseudoexfoliation glaucoma. PMID: 21510775
48. The R141L and G153D variations in the NH2-terminal region of LOXL1 do not affect the amine oxidase activity of LOXL1 associated with exfoliation glaucoma. PMID: 22328822
49. Spectroscopic results show that in all cases lysyl oxidase folds correctly but that the copper content, enzymatic activity, and redox-cycling ability depends on the mutation. PMID: 21190048
50. Transforming Growth Factor-Beta induces up-regulation expression of lysyl oxidase family in anterior cruciate ligament and medial collateral ligament fibroblasts. PMID: 21674292
顯示更多

收起更多
相關(guān)疾病：

Exfoliation syndrome (XFS)
亞細(xì)胞定位：

Secreted, extracellular space.
蛋白家族：

Lysyl oxidase family
組織特異性：

Expressed in ocular tissues including the iris, ciliary body, lens and optic nerve. Not detected in the retina.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 6665

OMIM: 153456

KEGG: hsa:4016

STRING: 9606.ENSP00000261921

UniGene: Hs.65436